Stocktoria

Valion Bio, Inc. VBIO

Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-2.17
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$780,000$1.2M$1.8M$1.3M
Gross profit$2,000$287,000$299,000-$38,000
Operating income-$7.9M-$4.5M-$8.2M-$10.1M-$5.6M
Net income-$8.9M-$5.7M-$8.2M-$10.1M-$8.5M
Operating cash flow-$7.0M-$5.7M-$8.5M-$8.9M-$5.6M
Free cash flow-$7.0M-$5.7M-$8.6M-$8.9M
Total assets$31.6M$2.8M$5.2M$5.9M$15.0M
Total liabilities$7.4M$272,000$1.6M$2.2M$1.8M
Shareholders' equity$16.8M$2.5M$3.6M$3.6M$13.3M
Ratios
Gross margin0.3%24.4%16.2%-3.0%
Operating margin-573.8%-701.1%-548.8%-448.1%
Net margin-725.0%-701.0%-548.7%-675.7%
FCF margin-734.0%-733.8%-485.3%
Return on assets-28.1%-201.5%-159.9%-171.8%-56.5%
Return on equity-52.9%-223.1%-230.3%-278.1%-64.0%
Current ratio20.139.703.322.8311.72
Revenue growth-33.7%-36.1%46.4%

Why these scores methodology →

Piotroski F-score: 3/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -2.17 (distress)

  • Working capital / assets 0.391
  • Retained earnings / assets -1.664
  • EBIT / assets -0.25
  • Equity / liabilities 2.258

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001787740 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.